Traders sold shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on strength during trading hours on Thursday. $59.43 million flowed into the stock on the tick-up and $132.39 million flowed out of the stock on the tick-down, for a money net flow of $72.96 million out of the stock. Of all companies tracked, Alexion Pharmaceuticals had the 0th highest net out-flow for the day. Alexion Pharmaceuticals traded up $2.22 for the day and closed at $123.34

Several research firms recently commented on ALXN. Cowen and Company reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Wednesday, June 8th. Zacks Investment Research raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 30th. Vetr raised Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $171.50 price target for the company in a research report on Wednesday, June 8th. Citigroup Inc. reissued a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, June 7th. Finally, Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $228.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, April 26th. Eight investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $193.55.

The stock’s 50 day moving average is $133.24 and its 200 day moving average is $146.20. The stock has a market cap of $27.63 billion and a PE ratio of 186.60.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, April 28th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.13 by $0.02. The business had revenue of $701 million for the quarter, compared to analysts’ expectations of $710.98 million. Alexion Pharmaceuticals’s revenue was up 16.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.28 earnings per share. On average, equities analysts expect that Alexion Pharmaceuticals Inc. will post $5.06 EPS for the current fiscal year.

In other Alexion Pharmaceuticals news, EVP John B. Moriarty sold 918 shares of the stock in a transaction on Monday, June 13th. The shares were sold at an average price of $135.72, for a total transaction of $124,590.96. Following the transaction, the executive vice president now directly owns 51,360 shares of the company’s stock, valued at $6,970,579.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Martin Mackay sold 4,097 shares of the stock in a transaction on Monday, May 16th. The stock was sold at an average price of $139.20, for a total transaction of $570,302.40. Following the transaction, the executive vice president now directly owns 42,706 shares in the company, valued at $5,944,675.20. The disclosure for this sale can be found here.

Other large investors have modified their holdings of the company. LS Investment Advisors LLC increased its stake in shares of Alexion Pharmaceuticals by 1.7% in the fourth quarter. LS Investment Advisors LLC now owns 5,257 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 89 shares in the last quarter. CG Asset Management LLC increased its stake in shares of Alexion Pharmaceuticals by 19.5% in the fourth quarter. CG Asset Management LLC now owns 6,750 shares of the biopharmaceutical company’s stock valued at $1,288,000 after buying an additional 1,100 shares in the last quarter. Sawtooth Asset Management Inc. increased its stake in shares of Alexion Pharmaceuticals by 15,072.9% in the fourth quarter. Sawtooth Asset Management Inc. now owns 7,283 shares of the biopharmaceutical company’s stock valued at $1,389,000 after buying an additional 7,235 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its stake in shares of Alexion Pharmaceuticals by 18.9% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 9,909 shares of the biopharmaceutical company’s stock valued at $1,890,000 after buying an additional 1,574 shares in the last quarter. Finally, Wetherby Asset Management Inc. increased its stake in shares of Alexion Pharmaceuticals by 0.5% in the fourth quarter. Wetherby Asset Management Inc. now owns 10,211 shares of the biopharmaceutical company’s stock valued at $1,948,000 after buying an additional 49 shares in the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.